Last reviewed · How we verify
Mejoral® 500 Tablets
Mejoral® 500 Tablets is a Small molecule drug developed by GlaxoSmithKline. It is currently in Phase 1 development.
At a glance
| Generic name | Mejoral® 500 Tablets |
|---|---|
| Sponsor | GlaxoSmithKline |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Mejoral® 500 Tablets CI brief — competitive landscape report
- Mejoral® 500 Tablets updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI
Frequently asked questions about Mejoral® 500 Tablets
What is Mejoral® 500 Tablets?
Mejoral® 500 Tablets is a Small molecule drug developed by GlaxoSmithKline.
Who makes Mejoral® 500 Tablets?
Mejoral® 500 Tablets is developed by GlaxoSmithKline (see full GlaxoSmithKline pipeline at /company/gsk).
What development phase is Mejoral® 500 Tablets in?
Mejoral® 500 Tablets is in Phase 1.
Related
- Manufacturer: GlaxoSmithKline — full pipeline
- Compare: Mejoral® 500 Tablets vs similar drugs
- Pricing: Mejoral® 500 Tablets cost, discount & access